Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPLENEVAC
2013-002631-19Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2014
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2 trial of pneumococcal 13-valent conjugate vaccine, Pneumo 23 and 23-valent pneumococcal polysaccharide vaccine in overwhelming post-splenectomy infection (OPSI) and invasive pneumococcal disease (IPD), sponsored by Assistance publique - Hôpitaux de Paris. Started Apr 2014; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccinePneumo 2323-valent pneumococcal polysaccharide vaccine
03
Conditions
overwhelming post-splenectomy infection (OPSI)invasive pneumococcal disease (IPD)
Beyond the preview
Go deeper on 2013-002631-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002631-19.